Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

20222,403 citationsJournal Articlebronze Open Access

Authors

Shanu Modi · Memorial Sloan Kettering Cancer Center

William Jacot · Inserm

Toshinari Yamashita · Inserm

Joohyuk Sohn · Inserm

María Vidal · Inserm

Eriko Tokunaga · Inserm

Junji Tsurutani · Inserm

Abstract

In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).

Topics & Keywords

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 1, pp. 9-20

DOI: 10.1056/nejmoa2203690

Field-Weighted Citation Impact: 235.05